Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4830 with pembrolizumab in advanced solid tumors
NCT03564691Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2018
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 12
01
Overview
Phase 1, open-label trial of mk-4830 in pancreatic adenocarcinoma (PDAC), mesothelioma, glioblastoma (GBM) and 7 more (17 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 27 months and 3 more. Started Jul 2018; status: completed.
02
Drugs
mk-4830
03
Conditions
pancreatic adenocarcinoma (PDAC)mesotheliomaglioblastoma (GBM)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03564691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564691.